Simplified Chinese
Warm congratulations to Minhai Biotechnology on being awarded the Second Prize of the 2024 Beijing Science and Technology Progress Award.
Release date:
2025-07-04
Author:
Source:
Abstract
Recently, the People’s Government of Beijing Municipality issued a notice regarding… Decision on the 2024 Beijing Municipal Science and Technology Awards. In this selection process, Beijing Minhai Biotechnology Co., Ltd. took the lead, with the China National Institute for Food and Drug Control, Jiangnan University, and the Jiangsu Provincial Center for Disease Control and Prevention jointly participating in its completion. of the “new type” Research and Development and Industrialization of the Pneumococcal Vaccine Series “Project” Awarded the Second Prize of the Science and Technology Progress Award This honor represents high recognition of the company’s groundbreaking technological innovations and their successful translation into practical applications in the biopharmaceutical field.
This project responds to the major national and Beijing municipal priorities and strategic plans for developing high‑end, sophisticated, and cutting‑edge industries. It has pioneered the establishment of a comprehensive process‑technology platform for the production of high‑price pneumococcal polysaccharide–protein conjugate vaccines, developed green and highly efficient polysaccharide‑preparation technologies, and, for the first time worldwide, introduced a dual‑carrier protein conjugation technology. It effectively avoids immune interference and enhances immunogenicity. Clinical trial results indicate that, Vaccine efficacy Superior to Foreign countries Similar products. Meanwhile, A comprehensive quality evaluation system has been established, encompassing national standard sugars, standard serums, and nuclear magnetic resonance–based polysaccharide analysis techniques.
Thanks to these innovative achievements, the project successfully overcame more than a decade of patent barriers and technological blockades imposed by multinational pharmaceutical companies, achieving domestic production of a multivalent pneumococcal conjugate vaccine and effectively addressing both import substitution and pressing public health needs. Notably, the 13-valent pneumococcal conjugate vaccine (PCV13) became the third such product globally. (Double carrier The first one ) , the first product in Beijing to receive market approval, since 2021 November Since entering the market, To date, the output value of individual products has exceeded 5.7 billion yuan. It has injected strong momentum into Beijing’s economic growth. , and has also provided a new technological “shield” to safeguard the lives and health of children nationwide.
This award was made possible thanks to City- and district-level governments Create of A favorable business environment and policies Support ， It has also injected new momentum into Minhai Bio’s scientific research and innovation, as well as the market expansion of its related products. Looking ahead, Minhai Biotechnology will Further integrate the company’s innovation resources, accelerate the development of new‑type productive forces, bolster new drivers of growth, and enhance the core competitiveness of the vaccine industry. We remain committed to innovating vaccine development, providing greater protection for people worldwide against the threat of infectious diseases, and making an even greater contribution to building a global community of health for all.
Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account